←
Kosj Yamoah MD, PhD934 posts
Kosj Yamoah MD, PhD avatar✓

Kosj Yamoah MD, PhD ✓

@KOSJ12

@MoffittNews Chair and Professor, Department of Radiation Oncology. Director, RO Cancer Health Disparities Research. Views are my own.

◷ Joined October 2015▧ 27 Photos and videos
Kosj Yamoah MD, PhD avatar
Kosj Yamoah MD, PhD@KOSJ12·Jul 24

Today marks an important milestone for our patients and community. The opening of the @MoffittNews Proton Center gives us another powerful tool to personalize cancer treatment with greater precision while helping protect healthy tissue. Proud of everyone who made this possible.

Post attachmentPost attachmentPost attachmentPost attachment
Moffitt Cancer Center avatar
⟳ Kosj Yamoah MD, PhD retweeted
Moffitt Cancer Center@MoffittNews·Oct 22

Today’s ribbon cutting celebrates the grand opening of the Moffitt Discovery and Innovation Center! This 250,000-square-foot facility at Speros in Pasco County creates new space for cancer research, collaboration and discovery. 💙

0:08
Moffitt Cancer Center avatar
⟳ Kosj Yamoah MD, PhD retweeted
Moffitt Cancer Center@MoffittNews·Oct 22

Florida Commissioner of Agriculture @WiltonSimpson highlights the Moffitt Discovery and Innovation Center’s role in advancing innovation and cancer care in Florida. Thank you for supporting our mission!

Post attachment
Moffitt Cancer Center avatar
⟳ Kosj Yamoah MD, PhD retweeted
Moffitt Cancer Center@MoffittNews·Sep 28

At #ASTRO26, Kolade Olabode, MD (@Kolade__Olabode) stops by the booth to present his poster on stage II-III NSCLC, with TP53 and BRCA2 mutations emerging as key genomic predictors of brain metastasis risk. A genomics-based model successfully identified high- and low-risk groups. Further study of molecular profiling for risk-adapted surveillance is needed. #MoffittASTRO26

2:15
Moffitt Cancer Center avatar
⟳ Kosj Yamoah MD, PhD retweeted
Moffitt Cancer Center@MoffittNews·Sep 28

🚨NEW from #ASTRO26: The phase 3 NRG-CC009 trial found median overall survival was 17.4 months with stereotactic radiosurgery vs. 8.6 months with hippocampal-avoidant whole-brain radiation for patients with small cell lung cancer and brain metastases. Moffitt’s Kolade Olabode, MD (@Kolade__Olabode), breaks down the findings and what they could mean for individualized treatment decisions. #MoffittASTRO26

0:58
Moffitt Cancer Center avatar
⟳ Kosj Yamoah MD, PhD retweeted
Moffitt Cancer Center@MoffittNews·Sep 28

From the #ASTRO26 poster session, Glebys Gonzalez, PhD, shares a dose-informed AI model that improved spatial radiation dose prediction from in vivo acoustic signals, outperforming conventional methods in preliminary patient testing. The model also demonstrated computational efficiency compatible with future real-time dose prediction workflows. #MoffittASTRO26

2:26
Moffitt Cancer Center avatar
⟳ Kosj Yamoah MD, PhD retweeted
Moffitt Cancer Center@MoffittNews·Sep 28

#LIVE from the #ASTRO26 plenary: Guang-Yi Sun, MD, opens the session with 10-year findings showing hypofractionated postmastectomy radiotherapy provided comparable disease control and survival to conventional fractionation in high-risk breast cancer, with acceptable long-term toxicity. The findings support hypofractionation as a safe and efficient treatment option. #MoffittASTRO26

Post attachmentPost attachment
Moffitt Cancer Center avatar
⟳ Kosj Yamoah MD, PhD retweeted
Moffitt Cancer Center@MoffittNews·Sep 28

🚨 New research being presented at #ASTRO26 provides randomized phase 3 evidence supporting fractionated radiosurgery for larger postoperative brain metastasis cavities. Moffitt’s Raj Upadhyay, MD (@aiims2738), discusses findings from the Alliance A071801 trial and what they could mean for improving local control and refining treatment for patients with brain metastases. #MoffittASTRO26 @ASTRO_org

2:19